End of Alzheimer's? Scientists hail new dementia drug that slows disease by a third

3 May 2023, 23:33 | Updated: 4 May 2023, 06:23

Scientists have hailed a 'hugely significant' new drug
Scientists have hailed a 'hugely significant' new drug. Picture: Getty/Alamy

By Kit Heren

The world is “on the cusp of a first generation of treatments for Alzheimer’s disease”, experts have said, as a new drug was found to slow cognitive and functional decline.

Listen to this article

Loading audio...

The drug donanemab, made by Eli Lilly and Company, slowed decline by 35% to 36% in a late-stage phase 3 clinical trial, the company said.

Donanemab appeared to slow the decline associated with Alzheimer’s compared with placebo in 1,182 people with early-stage disease based on those with intermediate levels of a protein known as tau.

The drug also resulted in 40% less decline in the ability to perform activities of daily living, according to the firm.

Almost half (47%) of those on donanemab had no clinical progression of disease at one year compared with 29% on placebo (defined as no decline in the commonly-used Clinical Dementia Rating Scale Sum of Boxes score).

Scientists are 'excited' about the possibilities presented by the new drug for treating people with Alzheimers
Scientists are 'excited' about the possibilities presented by the new drug for treating people with Alzheimer's. Picture: Alamy

Furthermore, participants on donanemab experienced a 39% lower risk of progressing to the next stage of disease compared to placebo, according to Eli Lilly.

In those patients receiving donanemab, brain swelling, a known side effect of drugs of this type, occurred in 24% of the participants, with 6.1% experiencing symptoms.

Brain bleeding occurred in 31.4% of the donanemab group and 13.6% of the placebo group.Lilly said the incidence of serious brain swelling in the donanemab study was 1.6%, including two participants whose deaths were attributed to the condition and a third who died after an incident of serious brain swelling.

It said most cases of swelling or bleeds were “mild to moderate” and responded to treatment.

Some 850,000 people in the UK have Alzheimers
Some 850,000 people in the UK have Alzheimers. Picture: Getty

Daniel Skovronsky, Eli Lilly’s chief scientific and medical officer, said: "This is the first phase 3 trial of any investigational medicine for Alzheimer’s disease to deliver 35% slowing of clinical and functional decline."

Dr Richard Oakley, associate director of research at the Alzheimer’s Society in the UK, said: “After 20 years with no new Alzheimer’s drugs, we now have two potential new drugs in just 12 months – and for the first time, drugs that seem to slow the progression of disease. This could be the beginning of the end of Alzheimer’s disease.

“Based on today’s early results, donanemab appears to slow the progression of Alzheimer’s symptoms by 36% (as compared with 27% of last year’s breakthrough drug lecanemab).

"Promisingly, the trial also demonstrated a 40% slowing in decline of everyday activities such as driving, doing hobbies and managing finances.

"While we’ve seen lecanemab could slow progression by over seven months, we’ll need to see the full results to know if donanemab could do the same or even better."

Caller lost faith after wife died from Alzheimer's

Dr Susan Kolhaas, executive director of research and partnerships at Alzheimer’s Research UK, said: “This is incredibly encouraging, and another hugely significant moment for dementia research.

“A second drug for Alzheimer’s has been shown to slow people’s cognitive decline in a rigorous phase 3 trial. We’re now on the cusp of a first generation of treatments for Alzheimer’s disease, something that many thought impossible only a decade ago.

Read more: New Alzheimer's drug Lecanemab hailed as ‘historic’ but questions remain about side effects and impact of use

Read more: New Alzheimer's drug Lecanemab hailed as ‘historic’ but questions remain about side effects and impact of use

"The treatment effect is modest, as is the case for many first-generation drugs, and there are risks of serious side effects that need to be fully scrutinised before donanemab can be marketed and used.

"However, this news underlines the urgency of preparing the NHS to make these treatments available should regulators deem them safe and effective.

"People should be really encouraged by this news, which is yet more proof that research can take us ever closer towards a cure.”

More Latest News

See more More Latest News

Max Verstappen has won his fourth F1 world title

Max Verstappen wins fourth F1 world title in Las Vegas Grand Prix

Keir Starmer has vowed to crack down on the 'bulging benefits bill'

Keir Starmer vows to crack down on 'bulging benefits bill' as he promises 'sweeping changes' to welfare system

Zvi Kogan

Body found in search for missing rabbi in UAE as Israel says he was killed in 'anti-Semitic terror incident'

Storm Bert has begun to make an impact with snow closing roads

Storm Bert to wreak more havoc as more than 200 flood warnings issued across the UK for Sunday

Island nations which are vulnerable to climate change and some African countries have stormed out of COP29 in a row over funding.

Deal struck for $300bn for developing countries at COP29 after talks had looked set to collapse

A number of unidentified drones have been spotted over three airbases in Britain, the United States Air Force (USAF) has confirmed.

Security alert after unidentified drones spotted above three US-run RAF bases

Two-thirds of Brits support the assisted dying bill which are set to be voted on in the House of Commons next week.

'Two-thirds support assisted dying bill' poll claims after Justice Secretary expressed concerns about proposals

Russia is prepared to launch a flurry of cyber attacks on Britain and other NATO members to weaken resolve in support for Ukraine, minister Pat McFadden is set to warn the alliance.

Russia 'prepared to bash Britain with massive cyber attack', ministers to warn NATO conference

Exclusive
Singer Kate Nash says she has joined adult content site OnlyFans to sell 'pictures of [her] arse' in an interview with LBC's Natasha Devon.

'Sex work is really empowering': Singer Kate Nash tells LBC why she sells photos on OnlyFans

The UK is on a 'slippery slope to death on demand', Justice Secretary Shabana Mahmood has said in a letter to constituents.

'Slippery slope to death on demand': Justice Secretary details concern over assisted dying debate

Novak Djokovic has appointed Andy Murray as his coach for the Australian Open.

Andy Murray to coach old rival Novak Djokovic at Australian Open after retiring in August

Island nations which are vulnerable to climate change and some African countries have stormed out of COP29 in a row over funding.

Negotiators from climate-vulnerable nations walk out of COP29 in row over funding deals

Putin has said he will fire more of Russia 's new hypersonic missiles at targets in Ukraine

Kremlin warns 'a collision between the nuclear powers' is imminent as West fires missiles into Russia

Coleen Rooney on I'm A Celeb

'Wagatha Christie strikes again': Coleen Rooney uncovers I'm A Celeb secret as she calls out campmates

Chloe Barlow is one of the small business owners who will be affected by the change

'It's a mess': Small businesses hit out at EU red tape set to cost thousands, and say 'government has been no help'

Foreign tourists ride on boat in a river in Vang Vieng

Laos government 'saddened' by deaths of tourists in Vang Vieng which include South London woman